Nephrotrans (Sodium Hydrogen Carbonate)

Sodium hydrogen carbonate dissociates into bicarbonate ions that bind hydrogen ions, forming carbonic acid which quickly breaks down into water and carbon dioxide. This raises the pH of blood, gastric secretions, and urine, thereby neutralizing excess acid and providing an overall alkalinizing effect.

The appropriate dose of Nephrotrans is determined by the prescribing healthcare professional based on the specific indication, patient age, renal function, and other clinical factors. Patients should follow the exact regimen advised by their prescriber and not adjust the dose on their own.

Safety of sodium hydrogen carbonate during pregnancy or lactation has not been definitively established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Nephrotrans, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nephrotrans provides sodium bicarbonate, a well‑characterized alkalinizing agent with rapid onset and predictable dosing. Compared with potassium‑based alkalinizers, it delivers sodium, which may be advantageous in patients needing sodium supplementation but requires caution in those with sodium‑sensitive conditions such as hypertension or heart failure.

Nephrotrans should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and ensure it is out of reach of children.

Nephrotrans is taken orally, usually with a glass of water. The exact timing—whether with meals or on an empty stomach—depends on the indication and the prescriber's instructions. Swallow tablets or capsules whole; do not crush or chew unless directed otherwise.

Serious risks include metabolic alkalosis, hypernatremia, severe electrolyte disturbances such as hypokalemia, and rare allergic reactions like rash or angioedema. Patients should be monitored for signs of these conditions, especially if they have renal impairment or are receiving other alkalinizing therapies.

Nephrotrans should be avoided in individuals with known hypersensitivity to sodium bicarbonate, uncontrolled hypertension, severe heart failure, or significant renal dysfunction where sodium load could be harmful. It is also contraindicated in patients already receiving high doses of other alkalinizing agents without medical supervision.